Phase IIa Clinical Study of N-Rephasin® SAL200

Stopped Enrollment into this study was terminated by the Sponsor prior to completion for strategic reasons.

Conditions

• Staphylococcus Aureus Bacteremia
• Anti-Bacterial Agents

Interventions

• BIOLOGICAL: N-Rephasin® SAL200
• OTHER: Placebo

Sponsor

Intron Biotechnology, Inc.